Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Gets Price Target Increase from Guggenheim

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target upped by Guggenheim from $89.00 to $97.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s price target would suggest a potential upside of 39.95% from the stock’s current price.

TARS has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, October 15th. Jefferies Financial Group boosted their price target on Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. HC Wainwright raised their price objective on Tarsus Pharmaceuticals from $88.00 to $106.00 and gave the stock a “buy” rating in a research note on Wednesday. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Finally, Barclays began coverage on Tarsus Pharmaceuticals in a research report on Wednesday, September 16th. They issued an “overweight” rating and a $110.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.57.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock traded up $0.24 during mid-day trading on Thursday, reaching $69.31. 158,206 shares of the company traded hands, compared to its average volume of 774,187. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.20 and a quick ratio of 3.17. Tarsus Pharmaceuticals has a fifty-two week low of $53.89 and a fifty-two week high of $91.53. The company has a market capitalization of $3.42 billion, a price-to-earnings ratio of -4.57 and a beta of 0.34. The firm’s fifty day moving average is $75.12 and its two-hundred day moving average is $67.85.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($14.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.46) by ($12.94). The company had revenue of $194.57 million during the quarter, compared to analysts’ expectations of $187.83 million. Tarsus Pharmaceuticals had a negative return on equity of 20.22% and a negative net margin of 102.93%. On average, equities research analysts expect that Tarsus Pharmaceuticals will post -2.23 earnings per share for the current fiscal year.

Insider Transactions at Tarsus Pharmaceuticals

In related news, Director William Link, PhD sold 12,500 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $78.38, for a total transaction of $979,750.00. Following the sale, the director directly owned 94,487 shares of the company’s stock, valued at $7,405,891.06. This trade represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 3,180 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $87.50, for a total value of $278,250.00. Following the sale, the insider directly owned 1,590 shares in the company, valued at approximately $139,125. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 48,031 shares of company stock worth $4,004,227 over the last quarter. 9.64% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Parallel Advisors LLC lifted its stake in shares of Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after purchasing an additional 291 shares during the period. Farther Finance Advisors LLC boosted its holdings in Tarsus Pharmaceuticals by 851.6% during the third quarter. Farther Finance Advisors LLC now owns 590 shares of the company’s stock worth $46,000 after buying an additional 528 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Tarsus Pharmaceuticals by 367.1% during the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock worth $50,000 after buying an additional 558 shares in the last quarter. Covestor Ltd grew its position in Tarsus Pharmaceuticals by 40.0% during the third quarter. Covestor Ltd now owns 1,095 shares of the company’s stock valued at $86,000 after buying an additional 313 shares during the period. Finally, State of Wyoming acquired a new stake in Tarsus Pharmaceuticals during the second quarter valued at $103,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose about 64% year over year to a record $194.6 million, above the cited $187.8 million consensus estimate. XDEMVY surpassed one million bottles dispensed and $1 billion in cumulative sales since launch. Tarsus Q3 financial results
• Positive Sentiment: Management forecast 2026 XDEMVY sales of $715 million to $730 million, supporting expectations for continued commercial growth. HC Wainwright raised its target to $106 and Oppenheimer lifted its target to $103; both maintained favorable ratings. 2026 XDEMVY sales outlook
• Neutral Sentiment: Tarsus is deferring planned Europe and Japan filings, delaying those potential expansion opportunities. International filing plans
• Negative Sentiment: The company’s reported Q3 net loss widened to $668 million, with acquisition costs cited as a major factor. Despite the revenue growth, coverage reported that shares fell after the results, suggesting the large loss overshadowed commercial progress for investors. Q3 net loss and XDEMVY sales

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.